Lower etanercept levels are associated with high Disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

Annals of the Rheumatic Diseases

Volumn 74, Issue 10, 2015, Pages 1825-1829

  Kneepkens, E L ^a   Krieckaert, C L M ^a   Van Der Kleij, D ^b   Nurmohamed, M T ^a,c   Van Der Horst Bruinsma, I E ^a,c   Rispens, T ^d   Wolbink, G J ^a,d  

^a Jan Van Breemen Research Institute/Reade   (Netherlands)

^b Sanquin Diagnostiek   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; AUTACOID; BIOLOGICAL MARKER;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; BLOOD; DRUG MONITORING; METABOLISM; MIDDLE AGED; PATIENT DROPOUTS; PROCEDURES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIRHEUMATIC AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; DRUG MONITORING; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 84942912018     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205213     Document Type: Article

References (24)

1. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
2. Navarro-Compán V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011;30:993-6.
3. Lee J, Noh JW, Hwang JW, et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010;29:1149-54.
4. Lee SH, Lee YA, Hong SJ, et al. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 2008;27:179-81.
5. Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71:1212-15.
6. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
7. Navarro-Sarabia F, Fernández-Sueiro JL, Torre-Alonso JC, et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 2011;50:1828-37.
8. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
9. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531-5.
10. Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:661-8.
11. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
12. Braun J, Pham T, Sieper J, et al.; ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
13. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-18.
14. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
15. Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
16. Fagerli KM, Lie E, van der Heijde D, et al. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology (Oxford) 2012;51:1479-83.
17. Olivieri I, D'Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev 2013;12:691-3.
18. Arends S, van der Veer E, Kallenberg CG, et al. Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol 2012;24:290-8.
19. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009;68:1787-8.
20. de Vries MK, Wolbink GJ, Stapel SO, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007;661:133-4.
21. Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol 2013;9:949-58.
22. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-15.
23. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004;42:267-76.
24. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.